ACHV Company Profile and Key Details

Achieve Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.14. This means the shares are trading above this model’s fair value.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) closed at $4.78 USD, gaining $1.23 (34.51%) from the previous close of $3.55. The stock is currently mid-range between its 52-week high and low $1.95 and $6.03. With a market capitalization of about $254.22 million, Achieve Life Sciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 673.04 thousand shares, trading with heavier-than-usual volume. Headquartered in Vancouver, BC, Achieve Life Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard A. Stewart, the company employs approximately 25 people and listed since October 12, 1995. Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.

Our AI price prediction model suggests that Achieve Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.96%, with price expected at $3.07 by April 28, 2026, within a range of $2.65 to $3.52 3-Month Outlook: Projected rise of 28.53%, reaching $4.64 by July 13, 2026, with a range of $4.43 to $4.82. 1-Year Outlook: Projected gain of 232.69%, with price at $12.01 by April 14, 2027, within a range of $0.53 to $19.81.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) shares are up 10.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Achieve Life Sciences, Inc. trading at a premium to the broader market with a P/E of -3.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.33, suggesting 324.65% upside. Our AI forecast model points to short-term weakness (-14.96% over two weeks), a medium-term rise (28.53% over three months), and a longer-term gain (232.69% over one year), with expected trading ranges indicating moderate volatility.

Achieve Life Sciences, Inc. generated EPS of -$1.38 over the past year. Five-year average earnings growth is 50.01%. Wall Street analysts project EPS growth of 46.02% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.29. Next year's EPS is expected at $16.86. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $19.00 to $12.00. The high target offers 426.32% upside. The low target suggests 232.41% downside. The mean target is $13.75. This offers 280.89% upside. Achieve Life Sciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 17.94%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 13.64% in August 13, 2024.

Achieve Life Sciences, Inc. trades at a P/E ratio of -3.51, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.93 trading at moderately above to book value. The P/FCF stands at -3.88, also below market averages.